Clinical trials: Myeloid Leukemia in Relapse (Disorder)
Leukemia, Myeloid, Acute, Relapsed Adult AML
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
- Conditions
- Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
- Trial name
- NCT05305859
- Testing
- venetoclax combining chidamide and azacitidine (VCA)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
The purpose of this study is to determine safety, tolerability, dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory lymphoproliferative malignancies (LPM) or…
- Trial name
- NCT02238522
- Testing
- ZEN003365
- Where
- 4 sites in United States
- Sponsor
- Zenith Epigenetics
Leukemia
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating patients with acute myeloid…
- Trial name
- NCT00003131
- Testing
- chemotherapy, gemtuzumab ozogamicin
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
This is a phase 1 study of investigational drug CFI-400945 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT03187288
- Testing
- CFI-400945 Fumarate
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
This phase I trial is studying the side effects and best dose of GTI-2040 and high-dose cytarabine in treating patients with refractory or relapsed acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00070551
- Testing
- GTI-2040, cytarabine, pharmacological study
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of SJG-136 in treating patients with relapsed or refractory acute leukemia, myelodysplastic syndromes, blastic phase chronic myelogenous leukemia, or chronic…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00301769
- Testing
- SJG-136
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory…
- Trial name
- NCT03896854
- Testing
- CART-19
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Leukemia
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005962
- Testing
- sargramostim, cyclophosphamide, cytarabine
- Where
- 65 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoid Leukemia, Myeloid Leukemia
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
This phase 2 trial studies the effect of intravenous (IV) vitamin C repletion after myeloablative allogeneic stem cell transplant.
- Conditions
- Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
- Trial name
- NCT03613727
- Testing
- Intravenous (IV) and oral Vitamin C
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Virginia Commonwealth University
Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase I/II trial studies the side effects and how well cladribine, idarubicin, cytarabine, and quizartinib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that is newly diagnosed…
- Conditions
- Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia
- Trial name
- NCT04047641
- Testing
- Cladribine, Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00002718
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
This phase II trial is studying how well giving 3-AP together with fludarabine works in treating patients with myeloproliferative disorders (MPD), chronic myelomonocytic leukemia (CMML), or accelerated phase or blastic phase…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia
- Trial name
- NCT00381550
- Testing
- fludarabine phosphate, triapine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
A Study of TAS1440 With ATRA in Subjects With r/r AML
This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent and in combination with all-trans retinoic acid…
- Trial name
- NCT04282668
- Testing
- TAS1440, TAS1440 + ATRA
- Where
- 8 sites in United States
- Volunteers
- 52 people
- Sponsor
- Taiho Oncology, Inc.
Leukemia, Myelodysplastic Syndromes
S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and how well patients will respond to treatment.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00919425
- Testing
- biologic sample preservation procedure
- Where
- 292 sites in United States
- Volunteers
- 1,294 people
- Sponsor
- SWOG Cancer Research Network
Acute Myeloid Leukemia
GilteRInf 2022 Study (Gilteritinib Related Infections)
The study is observational, retrospective-prospective, multicenter "real-life" study involving 26 centers belonging to the SEIFEM group.
- Trial name
- GilteRInf (NCT05791890)
- Testing
- Gilteritinib
- Where
- Italy
- Volunteers
- 78 people
- Sponsor
- University of Rome Tor Vergata
Leukemia, Myelodysplastic Syndromes
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy such as cytarabine use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00064090
- Testing
- cytarabine, triapine
- Where
- United States
- Sponsor
- Vion Pharmaceuticals
Leukemia
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00017589
- Testing
- oblimersen sodium, gemtuzumab ozogamicin
- Where
- United States
- Sponsor
- Genta Incorporated
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated…
- Conditions
- Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT05028751
- Testing
- Lanraplenib, Gilteritinib
- Where
- 17 sites in United States, Spain
- Volunteers
- 24 people
- Sponsor
- Kronos Bio
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects, best dose of flotetuzumab and how well it works in treating patients with acute myeloid leukemia (AML) that has come back (recurrent) or has not responded to treatment (refractory).
- Trial name
- NCT04158739
- Testing
- Cytarabine, Flotetuzumab
- Where
- 19 sites in United States
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.